

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

DMB

Display Date	<u>4-9-01</u>
Publication Date	<u>4-10-01</u>
Certifier	<u>JAZ</u>

[Docket No. 98N-0787]

Parke-Davis Pharmaceutical Research et al.; Withdrawal of
Approval of 14 New Drug Applications and 13 Abbreviated New Drug
Applications; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.


SUMMARY: The Food and Drug Administration (FDA) is correcting a
notice that appeared in the FEDERAL REGISTER of September 25,
1998 (63 FR 51359). The document announced the withdrawal of
approval of 14 new drug applications and 13 abbreviated new drug
applications (ANDAs). The document inadvertently withdrew
approval of ANDA 80-025 for Sulf-10 (sulfacetamide sodium
ophthalmic solution, USP) 10% held by Ciba Vision, 11460 Johns
Creek Pkwy., Duluth, GA 30097-1556. FDA confirms that approval
of ANDA 80-025 is still in effect.

EFFECTIVE DATE: September 25, 1998.

NCR-1

FOR FURTHER INFORMATION CONTACT:

Olivia A. Pritzlaff,
Center for Drug Evaluation and Research (HFD-7),
Food and Drug Administration,
5600 Fishers Lane,
Rockville, MD 20857,
301-594-2041.



In FR Doc. 98-25713 appearing on page 51359 in the issue of Friday, September 25, 1998, the following correction is made: On page 51360, in the table, the entry for ANDA 80-025 is removed.

Dated: March 26, 2001
March 26, 2001.

CERTIFIED TO BE A TRUE
COPY OF THE ORIGINAL

A handwritten signature in black ink, appearing to be "J. Woodcock", written over a horizontal line.A handwritten signature in black ink, appearing to be "J. Woodcock", written over a horizontal line.

Janet Woodcock,
Director,
Center for Drug Evaluation and Research.